Professor Urs Giger, one of the most recognised names in veterinary haematology and transfusion medicine and co-founder of the AVHTM, was recently awarded the 2020 International Canine Health Lifetime Achievement Award. He is internationally renowned for his haematology, transfusion medicine and hereditary disease research which spans over three decades. He represents one of the last clinical scientists with such a broad range of clinical and laboratory expertise. His work on blood typing in cats has really increased our understanding of the AB (ABC) blood group system (and Mik), and his studies on DEA 1, Dal and Kai 1 & 2 in dogs made many realise the complexity of blood groups in dogs.

After receiving his award, Professor Giger said: “I am elated to be the 2020 ICHA Lifetime Achievement Awardee. The prestigious award should, however, recognise and honour my international veterinary collaborators and my many fellows and students who I had the pleasure to work with. I am very proud of them all and I could not have made so many contributions without them.”

Having worked at the University of Pennsylvania for 35 years, he officially retired last year, but plans to continue to research, publish original studies, mentor veterinary students and doctoral fellows, and lecture internationally. He has agreed to participate at the ACVIM Forum and AVHTM Special Interest Group. The AVHTM board and members congratulate him and wish him well in his retirement.

In light of the on-going COVID-19 pandemic the VECCS board have now decided that IVECCS 2020 is now going to be a completely virtual experience. Although this will come as a disappointment to many, there are advantages. Firstly, it will be significantly cheaper, being only $75 for VECCS member veterinarians, $40 for VECCS member techs, residents, interns and 1st year post-grad vets, with VECCS member students and techs being able to ‘attend’ for free. Secondly, lectures can be viewed ‘live’, but, if the timing isn’t convenient for you, you can watch when you like as they will be available on demand to watch until December 2020. Thirdly this means you won’t have those difficult decisions of which lecture to attend when there is more than one you want to go to at the same time, as you can catch them all! There is an AVHTM stream with Marie Claude Blais speaking on canine and feline blood typing and pre-transfusion testing, Erin Mays discussing fibrinolysis and the use of fibrinolytics and then a panel made up of Terri DeFrancesco, Erin Mays and Kathryn Phillips discussing ‘The Clot from 3 Perspectives: The Criticalist, The Cardiologist and The Radiologist’. So all round, it sounds like this is an opportunity to grasp!
UK Clinical Trial – Canine Lyophilized Platelets - enrolling now

Evaluation of StablePlate Rx® in thrombocytopenic canine patients: a multicenter clinical trial

A UK trial is recruiting for specific thrombocytopenic cases across 9 UK veterinary centres.

This trial follows on from a US clinical trial in 2017 into severely thrombocytopenic, actively bleeding canines that concluded with the finding – A novel trehalose stabilized canine lyophilized platelet product is logistically and clinically non inferior to one of the current standard of care platelet products available in the US for canines (DMSO cryopreserved platelets) for management of thrombocytopenic bleeding in dogs.

https://www.eventscribe.com/2020/ACVIM/fsPopup.asp?efp=TlVXSkhZQ1o5ODQ0&PosterID=272420&rnd=0.267311&mode=posterinfo

Background

Small Animal Practices, Referral, Emergency and Critical Care Centres and University hospitals involved in emergency medicine are currently managing haemorrhage due to primary haemostatic defects using drug treatment alongside fresh whole blood – very occasionally Platelet Rich Plasma is harvested from whole blood donations. Most haemorrhage is managed without transfused platelets due to lack of availability of a UK banked platelet product and the challenges involved with harvesting appropriate volumes of fresh whole blood. Platelet transfusion when available, may be preferable over whole blood administration, allowing the transfusion of an appropriate number of platelets to be therapeutic in severe thrombocytopenia.1,2

This study is being performed under a VMD ATC and is part of an MSc in Veterinary Clinical research:

Research Lead – Jenny Walton BVM&S MRCVS.

MSc Supervisors - Professor Richard Mellanby BSc BVMS PhD DSAM DipECVIM-CA FRCVS,
Simon Tappin MA VetMB CertSAM DipECVIM-CA FRCVS

Inclusion Criteria:

Canine patients will be evaluated and selected using a standardized bleeding assessment tool, DOGiBAT. This assessment tool can be utilized to assess bleeding in nine anatomical sites with a grade of 0(none) to 2(severe). Dogs must score a “2” in one area or a “1” in two or more areas to be included in the study.3 A practical example of a patient with a DOGiBAT score of 2 would be a patient with visible petechiation anywhere on the body and +ve blood on dipstick urinalysis.

○ Patients must also have a platelet count of 50,000/ul or less for inclusion.
○ Patients must demonstrate a normal PT and aPTT at the time of enrollment into the study.
○ Patients can have received appropriate clinician led standard medical management that has been initiated no more than 48 hrs prior to enrollment.
○ Medications Allowed: Steroid (intravenous, oral), cyclosporine (intravenous, oral), antibiotics, mycophenylate.

Exclusion Criteria:

○ Patients may not receive platelet containing blood products within the 72 hours before enrolment into the study.
○ Patients may not have a haematocrit <20% at the time of enrollment into the study.
○ Patients may not be less than 2kg or more than 45kg.
○ Patients may not be being treated for congestive heart failure (CHF) or primary hypertension at the time of enrollment into the study.
○ Excluded medications (prior to enrollment) are: Vincristine and Blood Products, Cyclophosphamide, IVlgG (human or canine) Tranexamic acid (TXA).
○ Patients may not have undergone surgery in the 48 hours prior to enrollment.

UK Clinical leads and Centres enrolling patients

Daniel Lewis MA VET MB Dip ACVECC cert VA - Vets Now Glasgow
Craig Breheny BVM&S Dip ECVIM-CA MRCVS - Edinburgh University
Simon Tappin MA VETMB cert SAM DipECVIM CA FRCVS - Dick White Referrals - Cambridgeshire
Karen Humm MA VETMB cert VA DipACVECC FHEA DipECVECC - Royal Veterinary College - London

Continued on Page 4
Recently Published Articles


AHVTM is an IRS approved 501(c)(3) nonprofit professional association composed of veterinarians, hematologists, academics, veterinary technicians, blood bankers, and interested public who desire to further scientific advances in transfusion medicine and veterinary hematology.

We engage in veterinary research, promote industry standards, develop guidelines for canine and feline blood collection and processing, and publish scientific research in peer-reviewed publications.

Visit us online to learn more about AVHTM!

**UK Clinical Trial - Canine Lyophilized Platelets** (continued from page 2)

Kevin Walton BVM&S MRCVS - Durham and Washington Vets4pets

Andrea DiBella Cert SAM DipECVIM-CA MRCVS - Southern Counties Veterinary Specialists - Hampshire

Linnaeus lead - Sophie Adamantos BVSc CertVA DipACVECC DipECVECC MRCVS

Linnaeus Hertfordshire (Davies) - Patricia Ibarrola DipECVIM CA DSAM - Davies Veterinary Specialists – Hertfordshire

Linnaeus Wakefield (Paragon) - Andrea Holmes BVSc DipECVIM-CA MRCVS - Paragon Veterinary Specialists – Wakefield

Linnaeus Birmingham (Willows) - Ludivine Boiron MSC DVM DAVECC DipACVECC MRCVS - Willows Veterinary Specialists – Birmingham


Please contact Jenny Walton – jwalton@bodevet.com for more information concerning this UK trial, with criteria or enrollment queries, or the clinical centres for referral of potentially suitable cases. Enrollment can only occur at the nominated centres after full informed consent is obtained from the owner of any prospective trial patient.

**AVHTM 60% off the Non-Member Rate Code:** AVHTMVIRTUAL20

Register as a non-member for VECCS and use this code (above) at check out for a 60% discount on the non-member base registration. A Veterinarian would pay $100 instead of $250.

This is a gift from VECCS for this year, recognizing that all of the veterinary community has been affected by the COVID-19 pandemic. VECCS wants to show their appreciation for every member of the veterinary community by supporting their commitment to elevating the level of patient care when it has become harder to do so.  ~ Elke, VECCS